No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
RAPT RAPT Therapeutics
- 1.070
- -0.060-5.31%
Close Mar 10 16:00 ET
- 1.080
- +0.010+0.93%
Post 17:15 ET
141.25MMarket Cap-0.34P/E (TTM)
1.170High1.060Low713.76KVolume1.130Open1.130Pre Close776.40KTurnover1.22%Turnover RatioLossP/E (Static)132.01MShares9.65452wk High0.74P/B62.54MFloat Cap0.78952wk Low--Dividend TTM58.45MShs Float51.210Historical High--Div YieldTTM9.74%Amplitude0.789Historical Low1.087Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
RAPT Therapeutics Analyst Ratings
H.C. Wainwright Maintains RAPT Therapeutics(RAPT.US) With Buy Rating, Maintains Target Price $10
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss
RAPT Therapeutics to Participate in Upcoming Investor Conferences
RAPT Therapeutics | 10-K: FY2024 Annual Report
RAPT Therapeutics | 8-K: RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results